申请人:Yadav Jhillu S.
公开号:US20130052137A1
公开(公告)日:2013-02-28
The invention relates to nanotubes and processes for making them and intermediates of a drug moiety or its derivative/s as a structural moiety with side chain/s capable of promoting self aggregation. The side chain/s are mono or a multiple of alkyl chain/s that are substituted or unsubstituted capable of creating self aggregating assemblies. A p-amino benzoic acid (PABA) moiety or derivative as a structural moiety of 4-alkylamido-N-pyridin-2yl-benzamide with a lauric or stearic side chain. 4-alkylamido-N-pyridin-2yl-benzamide and 4-Amino-N-pyridine-2 yl-benzamide, N-(Pyridine-2-yl)-4-dodecanamido-benzamide and N-(Pyridin-2-yl)-4-stearamidobenzamide are intermediates useful for in vivo Conjugation of an active ingredient, illustrated by Rhodamine B. With Rhodamine B as an active ingredient, nano-tubes prepared with lauric side chain, which show red fluorescence and is useful for in vivo tracking.
该发明涉及纳米管及其制备方法,以及药物基团或其衍生物的中间体作为结构基团,具有能够促进自聚集的侧链。这些侧链是单个或多个烷基链,可以是取代或未取代的,能够形成自聚集的组装体。一种对氨基苯甲酸(PABA)基团或其衍生物作为4-烷基氨基-N-吡啶-2-基苯甲酰胺的结构基团,具有月桂酸或硬脂酸侧链。4-烷基氨基-N-吡啶-2-基苯甲酰胺和4-氨基-N-吡啶-2-基苯甲酰胺,N-(吡啶-2-基)-4-十二烷酰基苯甲酰胺和N-(吡啶-2-基)-4-硬脂酰胺基苯甲酰胺是用于体内活性成分共轭的有用中间体,以罗丹明B为例。以罗丹明B为活性成分,用具有月桂酸侧链的纳米管制备,显示红色荧光,适用于体内追踪。